

INDEX

- abetalipoproteinaemia, peripheral polyneuropathy, 336
 - abscess
 - brain, 369–84
 - intramedullary, differential diagnosis, 231
 - acoustic neuromas, 199–203, 219
 - operative approaches, 200
 - presenting symptoms, 199
 - treatment and outcome, 202
 - activities of daily living (ADLs)
 - Barthel ADL Index, 16, 21
 - rating scale, 296–8
 - spinal cord injuries, 189–91
 - acyclovir
 - herpes simplex encephalitis, 388–90, 394
 - herpes zoster virus infections, 397
 - adenovirus encephalitis, 395
 - adriamycin, and sensory ganglionectomy, trigeminal neuralgia, 528
 - age, comparing outcomes, 6–7
 - alcohol-associated polyneuropathies, 339
 - Alzheimer's disease, 23, 73, 294–5
 - American Spinal Injuries Association (ASIA), ASIA/IMSOP standards key muscles/sensory points, 184
 - amnesia
 - post-encephalitic, pathological features, 392–3
 - post-traumatic (PTA), 443, 446
 - amyloid neuropathy
 - carpal tunnel syndrome, 347
 - familial amyloid polyneuropathy, 335–7
 - amyotrophic lateral sclerosis (ALS), 305–7
 - amyotrophy, diabetic neuropathy, 338
 - aneurysmal bone cyst, 234
 - aneurysms
 - angiography, 53
 - bleeding, 73
 - false, 96
 - Galen, with fistulas, 130
 - intracranial, 93–122
 - aetiology, 94–5
 - aneurysmal dome, 106
 - asymptomatic, 100–1
 - atherosclerotic, 114
 - cavernous carotid artery, 113
 - classification, 95–7
 - clinical presentations, 97
 - complete occlusion, 114
 - dissection, 96
 - fusiform, 96, 98, 107
 - giant, 95, 98, 114–15
 - mass effect, 97–8, 114
 - posterior circulation, 99, 106, 114
 - rupture, 99–100
 - surgical timing, 103–4
 - saccular, 55
 - treatment
 - direct clipping treatment, 101–2
 - factors affecting surgical outcome, 112–15
 - ischaemia risk, 108
 - proximal ligation, with/without bypass, 107–9
 - size/surgical outcome, 113
 - trapping, with/without bypass, 107–9
 - wrapping/coating option, 109
 - see also* endovascular therapy
- angiofibromas, endovascular therapy, 55
- angiography, 53–4
 - diagnostic evaluation, 54
 - see also* cerebral angiography
- angiomas *see* cavernous angiomas
- angioplasty, transluminal, 54
- ankylosing spondylitis *see* cervical spondylotic myelopathy
- anticoagulants
 - aetiology of ICH, 73
 - stroke prevention, 81–2
 - stroke risk factor, 66
 - triggering intra-infarct haematoma, 62
- antiplatelet agents, stroke prevention, 81–2
- APACHE system, 6
- aphasia, speech therapy effectiveness, 44
- arachnoiditis, 479
- arterial disease, embolic occlusion, 66
- arteriovenous fistulas, dural, 135–43
- arteriovenous malformations, 123–33

- angiography, 53
 - computed tomography, 123
 - early/late results, pre-treatment comparison, 127
 - endovascular therapy, 55
 - grading, 125–6
 - haemorrhage, 123–4
 - morbidity/mortality statistics, 124–5
 - MRI, 123
 - natural history, 123–4
 - spinal, dural
 - clinical features, 135–6
 - distribution by gender, 136
 - embolic occlusion, 139–43
 - intramedullary, 137, 138
 - pathophysiology, 145–6
 - treatment, 139–41
 - spinal, intradural, 143–51
 - arteriography post-treatment, 147
 - dorsal/ventral, surgical risk, 150
 - glomus type, 143
 - presentation and evolution, 144
 - treatment, 148–51
 - treatment, 125–8
 - type I, *see also* dural AVFs
 - unruptured, 124, 129
 - vein of Galen, 130–1
 - natural history, modes of treatment, 131
 - artery stenosis *see* occlusion
 - arthrodesis, pedicle screw implants, 282
 - arthropod-borne encephalitides, 395, 396
 - ASIA *see* American Spinal Injuries Association
 - aspirin
 - allergy, 72
 - stroke prevention, 81, 82
 - astrocytomas, 219–23
 - differential diagnosis, 231
 - low grade, outcome results, 222
 - treatment, 232–3
 - ataxia, bacterial meningitis, 361
 - atherosclerosis, stroke risk factor, 66
 - atrial fibrillation, stroke risk factor, 65
 - attributability, 4
 - autonomic neuropathies, 337–8
 - HSANs, 333
 - AVFs *see* arteriovenous fistulas
 - AVMs *see* arteriovenous malformations
 - axonal degeneration disorders, 329
 - azathioprine, controlled trials for MS, 250
 - back pain
 - facet rhizotomy, 483–5
 - ‘failed back’, DBS indications, 495
 - Bannwarth’s syndrome, Lyme disease, 344, 366
 - Barthel ADL Index, 16, 21
 - stroke, 76
 - Beck Depression Inventory and Scale, 23, 27
 - Becker muscular dystrophy syndrome, 312–15
 - Bell’s palsy (idiopathic facial paralysis), 346
 - HZV infections, 397
 - Borrelia burgdorferi*, Lyme disease, 344, 366
 - botulinum toxin, 591
 - bradycardia, contrast media, 51
 - bradykinesia score, nigral cell count, 293
 - brain abscess, 369–84
 - age and outcome, 377, 378
 - post-treatment epilepsy, 379
 - CFRs (case fatality ratios)
 - epilepsy and location of abscess, 376
 - infective agents identified, 377
 - location of abscess, 375
 - and neurological status at diagnosis, 370
 - number of abscesses, 380
 - and type of therapy, 372–3
 - and underlying pathology, 374
 - imaging, 49
- brain infarction, 61–2, 66–70
 - analysis by vascular territory, 68–70
 - borderzone, 69
 - cause
 - cardioembolism, 66
 - extracranial large-artery disease, 66–8
 - small-artery disease, 67
 - cerebral infarct with transient signs (CITS), 62, 71
 - computed tomography and MRI, 62
 - dural AVF, embolic occlusion, 141
 - haemorrhagic infarct, 62
 - hemispheric infarcts, 69
 - imaging, 48–9
 - intra-infarct haematoma, 62–3
 - PCA territory infarcts, superficial, 69
 - subcortical infarcts, anterior circulation, classification, 69
- brain injury
 - neuropsychological processes
 - course of recovery, 572–4
 - and recovery of function, 567–72
 - neuropsychological rehabilitation,
 - meta-analytic review, 574–7
 - rehabilitation, post-acute, 173–4
 - see also* head injury; stroke
 - brain ischaemia
 - imaging, 48
 - lacunes, 68
 - PET, 53
 - risk, trapping procedure, 108
 - secondary to vascular steal, 145
 - stroke, 61
 - brain tumours, 219–23
 - levels of intervention, 222
 - outcomes
 - analysis criteria, 220–2

- brain tumours, outcomes (*cont.*)
 - disease-specific, 221
 - primitive neuroectodermal tumour, 219–23
 - prognosis, age, 220
- brainstem
 - auditory evoked potential (BAEP), 241
 - auditory evoked responses (BAERs), bacterial meningitis, 360
 - infarcts, 70
 - intracerebral haemorrhage, 74
 - responses
 - abnormal, 473
 - see also* coma
- bromocriptine, pituitary tumours, 225
- calcium antagonists, stroke, 81
- capillary telangiectasia, 123
- cardiac failure, first stroke and recurrent stroke, 65
- cardiac inotropism
 - cardioembolism cause, 66
 - negative, contrast media, 51
- cardiovascular disease, stroke risk factor, 65–6
- carnitine deficiency, metabolic myopathies, 316
- carotid arteries
 - aneurysms, 93–122
 - natural history, 113
 - bruits, stroke risk factor, 65
 - embolism, artery-to-artery, TIAs, 71
 - endarterectomy, 1, 66, 72, 82–3
 - extracranial, 114
 - and meningioma, 199
- carotid body, glomus tumours, 210
- carotid cavernous fistulas, embolization therapy, 55
- carotid stenosis, stroke risk factor, 65–6
- carpal tunnel syndrome, 347
- cavernomas, MRI, 49
- cavernous angiomas, 123
 - spinal cord, 151–2
- cavernous malformations *see* cavernous angiomas
- cavernous sinus *see* carotid cavernous fistulas
- CD-4 antibodies, MS, 252
- central pontine myelinolysis, 240
- cerebellar ectopia, 478
- cerebellar infarcts, 70
- cerebellar tremor, 557–8
 - conversion to rest tremor, 551
- cerebral abscess *see* brain abscess
- cerebral amyloid angiopathy, aetiology of ICH, 73
- cerebral angiography, 47, 53–4
- cerebral arteries
 - ACA, 68–9
 - territory infarcts, 68
 - aneurysms, 107
 - computed tomography, 48
 - large hemispheric infarcts, 69–70
 - MCA, 68–9
 - PC vein bypass, 109
 - PCA, 69
 - STA-MCA bypass, 108–9
 - stenosis, imaging, 48
 - subcortical infarcts in the anterior circulation, 68–9
 - vasospasm, delayed, 110–12
 - anterior/posterior circulation, 112
 - delayed cerebral arterial vasospasm, 110–12
- cerebral AVMs *see* arteriovenous malformations
- cerebral cortex, plasticity studies, 567–8
- cerebral embolus, 98
- cerebral haemorrhage
 - AVM, 123
 - statistics and cause, 62
 - treatment, 97
- cerebral hemisphere lesion, coma, 463
- cerebral hypoxia, severe, reversal sign, 49
- cerebral infarct with transient signs (CITS), 62, 71
- cerebral lymphomas, HIV infection and AIDS, 402
- cerebral vasculitis, tuberculous meningitis, 365
- cerebral venous thrombosis, 73
- cerebrospinal fluid
 - IgG oligoclonal bands, 242
 - rhinorrhoea, CT, 49
- cerebrotendinous xanthomatosis, peripheral polyneuropathy, 336
- cerebrovascular accident *see* stroke
- cerebrovascular disease, coma, 465–6
- cervical decompression, 270–2
- cervical discectomy, anterior, 272
- cervical puncture, myelography, 51
- cervical spondylotic myelopathy, 267–74
 - anterior/posterior approaches, compared, 273
 - corpectomy, 272–3
 - natural history, 268
- Chalfont Seizure Severity Scale, 25
- chemical meningitis, 205
- chemodectomas, 210–13
- chemonucleolysis, spinal degenerative disease, 277
- Chiari malformation, 478
- child abuse
 - shaken baby syndrome, 170
 - see also* head injury
- cholesterol level, stroke risk factor, 64
- chordomas and chondrosarcomas, 212–13, 234
 - mortality/morbidity after resection, 213
- chronic fatigue syndrome, 447–9
- chronic idiopathic axonal polyneuropathy (CIAP), 346
- chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 337, 341–2

- cigarette smoking
 - CHD risk, 65
 - stroke risk factor, 65
- clinical importance of interventions, 4–5
- clinical rating protocols
 - objective, 292
 - subjective, 290–2
- coagulopathies
 - acquired, 73
 - congenital, 73
- cobalamin deficiency, 339
- cognitive impairment
 - measurement questionnaires, 23
 - scale, Geriatric Mental State, 23
- colloid cysts, 207–10
 - clinical presentation, 207
 - microsurgical approaches, 210
 - treatment options, 209–10
- coma, 461–77
 - causes
 - drug coma, 464
 - head injury, 464, 468–471
 - hepatic coma, 466
 - hypoxic–ischaemic coma, 465
 - infections, 466
 - mass lesions, 466
 - medical coma, 464, 465, 471–4
 - clinical approach, 464–6
 - defined, 462
 - differentiation from
 - locked-in syndrome, 462
 - pseudocoma, 466–7
 - vegetative state, 462
 - Glasgow Coma Scale, 463
 - variations, 468
 - investigations
 - biochemistry, 474
 - EEG, 473
 - evoked potentials, 473
 - imaging, 474
 - outcomes, 467–74
 - and signs noted at time of admission, 472
 - paediatric scale, 467
 - pathogenesis, 462–4
 - prolonged, 469–70
 - Trauma Coma Data Bank (TCDB), 159, 161, 167
- complications of therapy scale, 301–2
- computed tomography, 47–9
 - compared with MRI, 48
 - elective/emergency diagnostic evaluation, 48
 - head injury, 159
- congenital vascular malformations *see*
 - arteriovenous malformations; cavernous haemangiomas
- contrast media, 51–2
 - Gd-DTPA, 52, 242
- copolymer-1, MS, 251
- cordotomy, percutaneous, 485–90
- coronary artery bypass surgery, in USA, 1
- coronary heart disease
 - risk indicators
 - cigarette smoking, 65
 - intermittent claudication, 65–6
 - stroke risk, 65–6
- corpus callosotomy, for epilepsy, 431–4
- corticotropin (ACTH)
 - in MS, 253
 - Nelson’s syndrome, 223
- cost-benefit analysis, 35–45
 - application to neurology, 43–5
 - benefit framework, 36–7
 - benefit measurement, 40–3
 - costs measurement, disease classification
 - codes, 37
 - Diagnosis Related Groups (DRGs), 37
 - extra-contractual referrals (ECR), 39
 - Goldberg’s General Health Questionnaire
 - opportunity cost, defined, 38
 - scarcity of resources, 36
 - single index/profile measures, 42
 - see also* CVA
- coxsackievirus meningitis, 385
- cranial nerve infections, herpes zoster virus,
 - 397–8
- cranial nerve palsies, tuberculous meningitis,
 - 364–5
- craniocerebral gunshot wounds, civilian,
 - outcome, 171–2
- craniopharyngiomas, 206
 - radical vs conservative therapy, 206
- creatine kinase, brain-type, in coma, 474
- Creutzfeldt–Jakob disease, 403
- CRIB scale, neonatal intensive care, 6
 - case fatality ratios (CFRs), 369–80
- critical illness polyneuropathies, 345–6
- CSM *see* cervical spondylotic myelopathy
- Cushing’s disease, 223–6
 - ketoconazole, 225
- CVA *see* stroke
- cyanoacrylate, embolic occlusion of spinal AVMs,
 - 141, 149
- cyclophosphamide, in MS, 250
- cyclosporin, in MS, 250
- deafness, bacterial meningitis, 359–60
- deep brain stimulation, pain control, 494–6
- degenerative brain disease, 289–304
 - clinical scoring protocols, 290–2
- degenerative spinal disease, 240, 267–88
 - spondylolisthesis, 281
- dementia
 - cerebral amyloid angiopathy, 73
 - PET, 53
 - see also* Alzheimer’s disease

- demyelinating disorder, 329, 343
 - central pontine myelinolysis, 240
 - HIV-associated, 343
- dense artery sign *see* thromboembolism, major cerebral artery
- deoxyspergualine, MS, 252
- dermoid cysts, tumours of developmental origin, 205–6
- developmental tumours, 205–10
 - colloid cysts, 207–10
 - craniopharyngiomas, 206–7
 - dermoid and epidermoid cysts, 205–6
- Devic's syndrome, 240
- diabetic neuropathy, 337–8
 - amyotrophy, 338
- diet, stroke risk, 65
- diffuse axonal injury, 442
- disability
 - assessment, head injury, 443–5
 - Barthel ADL Index, 16
 - defined, 582
 - outcomes of stroke, 76–7
 - and rehabilitation, 592
- disabling illness model, 582
- disc herniation, 275
- DM *see* dermatomyositis
- dopamine agonists, growth-hormone-secreting tumours, 225
- dopamine depletion, IP, 291
- Doppler sonography, 52
 - embolization therapy, 55
 - evaluation, 53
 - history, 47
- dorsal column stimulation, pain control, 493–4, 533–46
- dorsal root ganglia, inflammatory sensory neuropathy, 343
- DRGs *see* Diagnosis Related Groups
- drug-induced coma, 464, 468
- Duchenne muscular dystrophy syndrome, 310–14
- dural arteriovenous fistulas, 135–43
- dural arteriovenous malformations, 128–30
- dystonia musculorum deformans (DMD), thalamotomy, 558–60
- dystrophin-glycoprotein complex (DCG), 312
- dystrophinopathies (Xp21 deletions), 312
 - see also* muscular dystrophy
- echovirus meningitis, 385
- ECRs *see* extra-contractual referrals
- ECST *see* European Carotid Surgery Trial
- effectiveness
 - defined, 4
 - of outcomes, in rehabilitation of stroke, 587–90
- efficacy, defined, 4
- electrophysiology
 - EEG telemetry, in epilepsy, 422
 - in prognosis of coma, 473–4
- embolic occlusion *see* endovascular therapy
- encephalitis
 - adenovirus, 395
 - arthropod-borne, 395, 396
 - enterovirus, 396
 - herpes simplex, 385–94
 - intracranial pressure monitoring, 391
 - measles, mumps, rubella, 394–5
 - subacute sclerosing panencephalitis (SSPE), 395
- encephalopathies, transmissible spongiform, 403
- endorphins, PVG stimulation, 495
- endovascular therapy, 54–6
 - aneurysms, 113–15
 - balloon occlusion, 108
 - cerebral aneurysms, 106–9
 - embolic occlusion of intracerebral AVMs, 66
 - embolic occlusion of spinal AVMs
 - dural AVFs, 139–43
 - intradural, 148–51
 - risks, 141, 149–50
 - neuroradiological treatment, GDC, 106–9
 - ophthalmic internal carotid artery aneurysms, 113–14
 - stroke, 80–1
- enteroviruses, 396
 - meningitis, 385
 - persistent virus theory, 396
- entrapment neuropathies, carpal tunnel syndrome, 347
- ependymoblastoma, 219–23
- ependymomas
 - diagnostic imaging, 231
 - differential diagnosis, 231
 - treatment, 232–3
- epidermoid cysts, tumours of developmental origin, 205–6
- epilepsy, 407–40, 24–9
 - classification
 - seizure types, 408, 410–11
 - syndromes, 408, 412–13
 - efficacy of prophylaxis, 173
 - Epilepsy Surgery Inventory, ESI-55, 28
 - functional ability, 26
 - health status, quality of life, 27
 - herpes simplex encephalitis in children, 394
 - investigations
 - EEG telemetry, 422
 - magnetic resonance imaging, 49
 - neuroimaging, 423–4
 - PET, 53
 - location of brain abscess, CFRs, 376
 - outcomes
 - assessment, scales commonly used, 25
 - recurrence rates, 409–13
 - outcomes, medical, 408–20

- relapse, discontinuation of anticonvulsants, 417–19
- remission, 415–17
- outcomes, surgical, 24–5, 27, 420–34
 - corpus callosotomy, 431–4
 - extratemporal resection, 424–5
 - focal cortical resections, 420
 - hemispherectomy, 429–31
 - long-term, 425–6
 - neuropsychological tests, 426–7
 - physical indicators, 25–6
 - psychosocial outcome, 426
 - quality of life and employment, 427–9
 - temporal lobectomy, 421–9
- post-traumatic, 172–3
 - classified, 172
 - computed tomography, 48
 - late, 172
 - paediatric, 173
- post-treatment, brain abscess, 379
- psychiatric status, 26
- psychological and social measurements, 26–7
- seizure severity scales, 25–6
- and stroke, 18–24
- Washington Psychosocial Inventory, 28
- Epstein–Barr virus infection, meningitis, 385
- equine encephalitides, 396
- erythema chronicum migrans, Lyme disease, 344, 366
- Escherichia coli*, neonatal meningitis, 362–3
- ESI *see* Epilepsy Surgery Inventory
- essential tremor, 557–8
- estrogens *see* oral contraceptives
- ethnicity, comparing outcomes, 6–7
- European Carotid Surgery Trial (ECST), 82–3
- Fabry’s disease, peripheral polyneuropathy, 336
- facet rhizotomy, 483–5
- facetotomy, medial, lumbar stenosis, 278
- facial pain, *see also* pain syndromes; trigeminal neuralgia
- facial paralysis
 - idiopathic, 346
 - Lyme disease, 344, 366
- familial amyloid polyneuropathy (FAP), 335–7
- fatal familial insomnia, 403
- fibrinogen level, risk factor for stroke, 65
- firearm-related brain injury, 171–2
- foramen ovale, patent, embolic occlusion, 67
- foraminotomy, lumbar stenosis, 278, 280
- Forbes–Albright syndrome (amenorrhoea-galactorrhoea), 223
- Frankel Classification
 - admission/discharge, 183
 - cervical spine injuries, 182–3
 - spinal cord injuries, 181–2
- functional independence measure (FIM), 183
- Functional-Economic Outcome Rating Scale, spinal conditions, 276
- gadolinium diethylenetriputaetic acid (Gd-DTPA), 52, 242
- Galen aneurysms with fistulas, 130
- ganglionitis, 342
- gasserian ganglion, chronic neurostimulation, trigeminal neuralgia, 528
- gate control theory, and spinal cord stimulation, 533
- GCS *see* Glasgow Coma Scale
- GDC *see* Guglielmi detachable coils
- general paresis, syphilis, 365
- genital herpes, 388
- Geriatric Mental State scale, 23
- germ cell tumours, 220
- Gerstmann–Straussler–Scheinker disease, 403
- Glasgow Coma Scale, 159–60, 463
- Glasgow Outcome Scale, 18, 101, 164, 166–7
- glioblastoma, 219–23
- gliomas, 50, 219–20
 - outcome results, 221
 - patient age importance, 220
 - radiotherapy, 223
- glomus tumours, 210–13
 - classified, 211
 - embolization therapy, 55
 - jugulare, resection complications, 211
 - see also* chemodectomas
- D-glyceric acidemia, 412
- gonadotrophic (FSH/LH) related tumours, 223
- GOS *see* Glasgow Outcome Scale
- growth-hormone-secreting tumours, 223–6
- Guglielmi detachable coils, 55, 115, 114
- Guillain–Barré syndrome, 340–1
- haemangioblastomas
 - diagnostic imaging, 231
 - treatment, 232–3
- haematin, porphyrias, 335
- haematomas
 - epidural/subdural, 47
 - intra-infarct, 62–3
- haematomyelia, ascending, 187
- haemodialysis, 41
- Haemophilus influenzae*, bacterial meningitis, 357–62
- Hamilton Depression Scale, 26
- handicap, and rehabilitation, 593
- Harris’s syndrome (cluster headache), 453–6
- head injury, 157–80
 - assessment of symptoms and disability, 443–5
 - classification, 159
 - coma, 464, 468–471
 - firearm-related, 171–2
 - incidence and statistics, 157–8

- head injury (*cont.*)
 - outcome, 159–75, 441–2, 442
 - abnormal pupils, 161–2
 - assessment of outcome, 164
 - coma, 468–71
 - correlation with age, 160–1
 - diagnostic abnormalities, 160
 - diffuse axonal injury, 162
 - hypotension, 162
 - intracranial diagnosis/outcome at discharge, 162
 - intracranial mass lesions, 163
 - intracranial pressure (ICP), 159–60
 - mild, 164–6, 446
 - moderate, 166–7
 - post-resuscitation GCS motor score, 160–1
 - post-traumatic epilepsy, 172–3
 - pre-injury/social history influence, 163
 - prediction, 158
 - return to work and PTA, 446
 - severe, 167–8
 - severe closed injury, 443, 446
 - paediatric, 168–71
 - non-accidental injury, 170–1
 - post-traumatic epilepsy, 441–7
 - prognosis, 445–7
 - rehabilitation, 173–4
 - severe, criteria, 443
 - tests of neuropsychological impairment, 444–5
- headache, 449–57
 - cluster headache, 453–6
 - definitions, 457
 - hindbrain-related syringomyelia, 478–9
 - migraine, 451–3
 - tension headache, 449–51
- health services
 - constraints, 36
 - cost-benefit analysis, 35–45
 - cost measurement, 37–40
- health status
 - concept, 15–16, 41–2
 - global index, 14
 - indicators, criteria for selection, 16–17
 - which measure?, 17–18
 - scales, 18
- hearing loss, bacterial meningitis, 359–60
- hemifacial spasm, microvascular decompression, 547
- hemispherectomy, for epilepsy, 429–31
- heparin, stroke, 81
- hepatic coma, 466
 - outcomes, 471–4
- hereditary motor and sensory neuropathies, 330–7
 - HMSN types 1, 2 and 3, 331–2
 - HNPP, 333
 - with liability to pressure palsies (HNPP), 333
 - sensory and autonomic neuropathies, 333
 - X-linked HMSN, 333
- herniated lumbar disc, 274–7
 - chemonucleolysis, 277
 - conventional laminotomy, 276
 - discectomy
 - microsurgical, 276–7
 - percutaneous, 277
 - evaluation of outcome, 276
 - Functional-Economic Outcome Rating Scale, 276
 - see also* spinal degenerative disease
- herpes simplex encephalitis, 385–94
 - adult/older child infections, HSV-1, 387
 - investigations
 - computed tomography, 49
 - MRI, 392
 - morbidity
 - prognostic factors, 393
 - treated, 392
 - untreated, 387
 - mortality, 387–8
 - treated, 389
 - untreated, 387
 - neonatal and fetal infections, HSV-1 or HSV-2, 387, 388–90
 - outcomes
 - laboratory parameters, 391
 - neonatal and fetal infections, 389–90
 - neurological sequelae, 391–4, 392
 - predictors, 390
 - primary genital herpes, 388
 - relapse, 394
- herpes zoster virus infections, 397–8
 - HIV infection and AIDS, 398
- heterotopias, MRI, 50
- hindbrain herniation, 478
- hindbrain-related syringomyelia, 478–9
- hippocampal formation, MRI-based volumetry, 393
- HIV infection and AIDS, 398–403
 - cerebral lymphomas, 402
 - independent predictors, women, 399
 - mortality rate, treated CNS infections, 400
 - opportunistic infections, 398–401
 - paediatric infections, 402–3
 - peripheral neuropathies, 343–4
 - progress of HIV encephalopathy, 398–9
- HLD *see* herniated lumbar disc
- Hoehn and Yahr staging, CNS diseases, 303
- hormone replacement therapy, stroke risk, 65
- Horton’s syndrome (cluster headache), 453–6
- Hospital Anxiety and Depression Scale (HAD), 22
- hospital discharge planning, 591
- hospitals
 - comparing outcomes, 5–6
 - ‘league tables’, 3

- HTLV-1-associated myelopathy, 397
- human T-cell lymphotropic viruses, 396–7
- hydrocephalus
 - computed tomography, 100, 110
 - MRI, 110
 - ventriculoperitoneal (VP) shunting, 206
- hydrocephalus, obstructive, tuberculous meningitis, 364–5
- hypertension
 - acute, aetiology of ICH, 72–3
 - chronic
 - aetiology of ICH, 72
 - stroke risk factor, 64–5
- hypopituitarism, post-radiation therapy, 225
- hypoxic–ischaemic coma, 465
- IBM *see* inclusion body myositis
- ICH *see* intracerebral haemorrhage
- ICP *see* intracranial pressure
- IgA, IgG, IgM-associated monoclonal gammopathies, 345
- IgG oligoclonal bands, cerebrospinal fluid, MS, 241
- illness, model, 582–4
- immunosuppressive therapy, neuromuscular disease, 311
- impairment, and rehabilitation, 591–2
- inclusion body myositis, 310
- inflammatory myopathies, neurological disease, 309–11
- inflammatory sensory neuropathy (ganglionitis), 342
- insomnia, fatal familial, 403
- interferons, MS, 251
 - disability progression, 251–2
- interleukin-2, disease progression of MS, 252
- intermittent claudication, stroke risk, 65–6
- International Medical Society of Paraplegia (IMSOP), 182–3
- interventional neuroradiology, 54
- intracavernous aneurysms, and ophthalmic internal carotid artery, 112–13
- intracerebral haemorrhage, 72–5, 123
 - aetiology, 72–3
 - clinical presentation, 73–5
 - brainstem, 74
 - cerebellar, 74
 - deep supratentorial, 74
 - lobar, 74
 - traumatic, 73
 - vascular malformations, 73
 - diagnosis, 75
 - prognosis, 75
 - treatment, 75
 - see also* endovascular therapy
- intracranial aneurysms
 - aetiology, 94–5
 - classification, 95–7
 - clinical presentations, 97
 - giant, 95, 98, 114–15
 - incidence, 93–4
 - intracavernous artery, 112–13
 - ophthalmic artery, 112–13
 - surgical options and outcome, 101–9
- intracranial cysts, surgical results, 206
- intracranial pressure, monitoring, 159–60, 391
- intraventricular haemorrhage, mass effect, 98, 105
- IP *see* Parkinsonism, idiopathic
- ischaemic heart disease, first and recurrent stroke, 65
- jugular neuroma, 205
- Karnofsky Performance Scale, 21, 221
- Kluver–Bucy syndrome, following HSV infection, 392, 393
- Korsakoff’s psychosis, following HSV infection, 392
- Krabbe’s disease, peripheral polyneuropathy, 336
- kuru, 403
- lacunar syndrome, 69, 73
- Lambert–Eaton myasthenic syndrome (LEMS), 309
- laminectomy
 - cervical, 269–72
 - decompressive, 280
 - lumbar stenosis, 278
 - spinal degenerative disease, 268
 - spinal tumours, 228–30, 235
- laminotomy, conventional spinal, 276
- lemniscal system, deep brain stimulation, 495
- leprosy, 344–5
- levodopa therapy, Parkinson’s disease, 290
- life satisfaction, definition and scales, 23–4
- linoleic acid, diet supplement, MS, 252
- lipid storage diseases, 239–40
- lipomas, treatment, 232
- Listeria monocytogenes*
 - meningitis, 363
 - neonatal meningitis, 362–3
- liver transplantation, in familial amyloid polyneuropathy, 335
- locked-in syndrome, differentiation from coma, 462
- lumbar discectomy, degenerative spinal conditions, 275
- lumbar instability
 - fusion, 281
 - pseudarthrosis, 281
- lumbar stenosis, 278–81
 - decompression extent, 279–80
 - facetectomy, medial, 278

- lumbar stenosis (*cont.*)
 - foraminotomy, 278
 - long term outcome, 278–9
 - surgical outcome/patient selection, 280
- Lyme disease, 344, 366
- macroadenomas, hypopituitarism link, 224
- magnetic resonance imaging (MRI), 48–51, 49–51
 - angiography and functional imaging, 47
 - cost-benefit analysis, 43–4
 - diagnostic evaluation, 51
 - embolization therapy, 55
 - paediatric, 50
- malingerer, 445
- McArdle’s disease, 316
- measles encephalitis, 394–5
- medial thalamotomy, 492–3
- medical coma *see* coma
- MEDIS group, 6
- medulloblastoma, 219–23
- meningeal disease
 - fibrosis, 479
 - gumma in syphilis, 365
 - MRI, 50
- meningioma, 197–9, 219–23
 - cervical, 229
 - grading, symptomatic recurrence risk, 196
 - incidence and clinical signs, 227–8
 - incidence increase, elderly population, 220
 - morbidity/mortality, 199
 - outcome results, 223
 - recurrence, 197
 - resection
 - incomplete, 198
 - mortality/principal morbidity, 200
 - treatment, 228–30
 - embolization therapy, 55
- meningitis, chemical, 305
- meningitis, bacterial, 357–68
 - coma, 466
 - epidemiology, 357–8
 - hearing loss, 359–60
 - Lyme disease, 344, 366
 - major sequelae, 357, 361–2
 - neonatal meningitis, 362–3
 - outcomes in HIV infection and AIDS, 400
 - seizures, 361
 - tuberculous meningitis, 364–5
- meningitis, viral, 385, 386, 466
- meningoradiculitis, spirochaete-associated, 344
- mesencephalic tractotomy, 490–1
- metabolic myopathies, 316
- metachromatic leukodystrophy, peripheral
 - polyneuropathy, 336
- microvascular decompression
 - hemifacial spasm, 547
 - trigeminal neuralgia, 516–22
- migraine stroke, causes, 67
- misoprostol, MS, 256
- mixed connective tissue disease, trigeminal
 - neuropathy, 343
- mobility aids, 593
- model of illness, 582–4
- monoclonal gammopathy-associated
 - neuropathies, 345
- mononeuropathies, 328, 338, 346–8
- morphine screening test, 495
- motor examination, rating scale, 298–301
- motor neurone disease (MND), 305–7
- motor neuropathy, multifocal, 342
- movement disorders, stereotactic surgery, 547–66
- MPTP, nigrostriatal lesions, 293
- multifocal motor neuropathy, 342
- multiple sclerosis, 239–66
 - background and statistics, 239
 - brain stem auditory evoked potential (BAEP), 241
 - cerebellar tremor, 557–8
 - clinical course, 240
 - cognitive impairment, 254
 - cost-benefit analysis, 43
 - course of disease, prediction, 243–4
 - demyelinating disorders, 239–40
 - development forecast, 242–3
 - diagnosis, 240–2
 - investigations, MRI, 36, 50
 - mortality, 247
 - neuromodulation, 257–8
 - optic neuritis, 242, 253
 - pregnancy, 247
 - progression forecast, 242–3
 - progression phase, 244–6
 - relapse
 - acute/appropriate treatment, 253–4
 - environmental factors, 246–7
- remyelination, axonal loss prevention, 248
- somatosensory evoked potential (SSEP), 241
- symptomatic management
 - ataxia, 256
 - bladder dysfunction, 256
 - dysphagia, 257
 - fatigue, 255
 - paroxysmal symptoms, 256
 - spasticity, 255–6
- therapeutic approaches, 247–8
 - azathioprine, controlled trials, 250
 - copolymer-1, 251–2
 - cyclophosphamide, 250
 - cyclosporin, blind trials, 250
 - immunotherapy, 249
 - influencing immune system, 248–53
 - interferon beta-1b, and disability
 - progression, 251–2
 - interleukin-2, disease progression, 252

- linoleic acid, diet supplement, 252
- visual evoked potential (VEP), 241
- mumps, 394–5
- muscular dystrophy *see* Becker; Duchenne
- myalgic encephalomyelitis, 447–9
- myasthenia gravis, 307–9
- Mycobacterium tuberculosis*, tuberculous meningitis, 364–5
- myelin basic protein (MBP), MS, 252
- myelin metabolism, MRI, 50
- myelin-associated glycoprotein (MAG), 345
- myelography, 44, 51
 - cost comparison with MRI, 51
 - diagnostic evaluation, 53
 - history, 47
 - side effects, 51
- myoneural junction disorders, 307–9
- myotonic dystrophy, 315–16

- neglect alert device, 577
- Neisseria meningitidis*
 - bacterial meningitis, 357–62
 - elderly patients
- Nelson’s syndrome, corticotropin (ACTH), related, 223
- neonatal intensive care, CRIB scale, 6
- neonatal meningitis, 362–3
- neonatal mortality, 2
- nerve sheath tumours, 199–205
- neurological disease, chronic *see* degenerative diseases
- neurological imaging, 47–56
- neuromuscular diseases, 305–16
 - immunosuppressive therapy, 311
 - natural history and therapy, 306
- neuron-specific enolase, 474
- neuropathies, 328–56
 - alcohol-associated, 339
 - asymmetric, 338
 - autonomic, 337–8
 - axonal degeneration disorders, 329
 - chronic inflammatory demyelinating
 - polyradiculoneuropathy, 337, 341–2
 - demyelination disorders, 329
 - diabetes-associated, 337
 - focal and multifocal, 338
 - gene defects, 328
 - hereditary, 330–7
 - familial amyloid polyneuropathy (FAP), 335–7
 - HMSNs, 331–2
 - HSANs, 333
 - porphyrias, 334–5
 - with pressure palsies (HNPP), 333
 - rare metabolic disorders, 335, 336
 - monoclonal gammopathy-associated, 345
 - mononeuropathies, 338, 346–8
 - defined, 328
 - nutritional deficiency-associated, 339–40
 - partial lesions, 329
 - symmetrical, 337–8
 - systemic disease-associated, 337–9
 - toxic, 346
 - trigeminal neuralgia, 343, 507–32
 - see also* peripheral neuropathies
- neuropsychological impairment, course of recovery, 572–4
- neuropsychological processes
 - compensation, 569
 - functional adaptation, 569–72
 - inhibition, 568–9
 - motivation and emotion, 572
- neurosurgery
 - cost-benefit analysis, 35–46
 - application, 43–5
 - multiplicity of outcomes, 9
 - pain syndromes, 481–506
 - stereotactic, in movement disorders, 547–66
- nigrostriatal lesions, 293
- nimodipine, stroke, 81
- non-accidental paediatric head injury, 170–1
- North American Symptomatic Carotid Endarterectomy Trial (NASCET), 82–3
- Nottingham Health Profile, 10, 18

- oligodendroglioma, 219–23
 - outcome results, 222
- oncoretroviral disease, HTLV-I and II, 397
- ophthalmic internal carotid artery aneurysms, 112–13
- optic atrophy, syphilis, 365
- optic neuritis, MS, 242–3, 253
- oral contraceptives, stroke risk, 65
- orthoses, 593
- osteophylectomy, 271, 272
- otitis media, 360
- outcomes
 - and age, 6–7
 - and clinical importance of interventions, 4–5
 - definition and measurement, 4, 14–29
 - for individual, 3–4
 - multiplicity, 7–9
 - perinatal mortality, 2
 - problem of definition, 8

- paediatric neuroimaging, MRI, 50
- pain syndromes, neurosurgical treatment, 481–506
 - deep brain stimulation, 494–6
 - dorsal column stimulation, 493–4
 - facet rhizotomy, 483–5
 - intractable pain, 482–92
 - results and outcomes, 492–6
 - measurement of outcomes, 481–2, 487

- pain syndromes (*cont.*)
 - medial thalamotomy, 492–3
 - mesencephalic tractotomy, 490–1
 - mirror pain, 487–8
 - percutaneous cordotomy, 489–90
 - spinal cord stimulation, 533–46
 - trigeminal neuralgia, 507–32
 - pallidotomy, effect on bradykinesia, 547–8
 - parahippocampalgyrus. MRI-based volumetry, 393
 - paraplegia
 - defined, 181
 - International Medical Society of Paraplegia (IMSOP), 182–3
 - paraproteinaemia, inflammatory sensory neuropathy, 342
 - paravertebral extension, osseous involvement, MRI, 50
- Parkinsonism, idiopathic, 290–1, 294
 - clinical rating protocols, 291–2
 - dopamine depletion, 291
- Parkinson's disease, 290
 - levodopa therapy, 290
 - stereotactic surgery, 547–66
 - Unified Parkinson's Disease Rating Scale (UPDRS), 292, 295–303
- partial sensory rhizotomy, trigeminal neuralgia, 522–4
- pedicle screw implants, lumbar instability, 282
- percutaneous cordotomy, 485–90
- percutaneous procedures for trigeminal neuralgia
 - radiofrequency trigeminal gangliolysis, 512–14
 - retrogasserian glycerol rhizolysis, 510–12
 - trigeminal ganglion (micro)compression, 514–16
- perinatal mortality, 2
- periodic migrainous neuralgia (cluster headache), 453–6
- peripheral neuropathies, 328–56
 - brachial plexus injuries, 348
 - due to traumatic injury, 347–8
 - entrapment syndromes, 347
 - gene defects, 328
 - HIV-related, 343
 - and Lyme disease, 344
 - prevention and treatment, 330
 - rehabilitation, 330
 - stimulation, pain control, 533
 - symptoms and course, 330
 - underlying pathology, 329
- periventricular grey (PVG), deep brain stimulation, 495
- PET *see* positron emission tomography
- phenytoin, epilepsy, 173
- phobias
 - claimants post-injury, 444–5
 - travel anxiety, 444–5
- physical disability
 - assessment, head injury, 443–5
 - Barthel ADL Index, 16
 - disabling illness model, 582
 - progression in MS, 251–2
 - and rehabilitation, 592
- phytanic acid, 336
- pineal tumours, 220
- pineoblastoma, 219–23
- pituitary tumours, 219–20, 223–6
 - hormone levels, 224
 - intervention levels, 225–6
 - outcome post-surgery, 224
 - radiotherapy, 225–6
- plasma exchange, Guillain–Barré syndrome, 340–1
- plexopathies
 - defined, 328
 - Lyme disease, 344
- PM *see* polymyositis
- PNET *see* brain tumours, primitive neuroectodermal tumour
- pneumocephalography, history, 47
- pneumococcal meningitis, *Streptococcus pneumoniae*, 357–62
- poliomyelitis, 396
- polymyositis, 310–11
 - idiopathic, 312
 - underlying tissue disorders, 310
- polyneuritis, Lyme disease, 344
- polyneuropathies
 - alcohol-associated, 339
 - defined, 328
 - idiopathic, 346
 - monoclonal gammopathy-associated, 345
 - nutritional deficiency-associated, 339–40
 - sensorimotor, 343–4
 - symmetrical, 337–8
 - vasculitic neuropathy, 343
- polyvinyl alcohol (PVA) sponge, embolic occlusion of spinal AVMs, 141, 149
- porphyrias, 334–5
 - drugs and chemicals in, 334
- positron emission tomography, 52–3
 - and bradykinesia score, 293
 - indications, 54
- post-herpetic neuralgia, 397
- post-traumatic amnesia (PTA), 443, 446
- post-traumatic stress disorder, 444–5
- post-traumatic syndrome, 441–7
- primitive neuroectodermal tumour, 219–23
- prion disease, 403
- Prolo Scale *see* Functional-Economic Outcome Rating Scale
- proton spectroscopy, myelin metabolism, 50

- pseudarthrosis, lumbar instability, degenerative, 281
- PTE *see* epilepsy, post-traumatic
- pyrogenic myositis, 309
- quadraparesis, defined, 181
- Quality Adjusted Life Year (QALY), 41–2
 - old age, 2
 - problems of definition, 10
- quality of life, 15–16
 - definition, 14
 - epilepsy, 27
 - measurement (QOL), 40
- Quality of Well-being Scale, 21
- radiculoneuritis, spirochaete-associated, 344, 366
- radiculopathy, imaging, 51
- radiology, interventional, 54–6
- radionecrosis, MRI, 50
- radiotherapy, pituitary tumours, 225–6
- Ramsay Hunt syndrome, 397
- RAND Medical Outcomes Survey, 18, 29
 - eight item depression scale, 23
 - Short-Form-36 (SF-36), 18, 19
- Refsum’s disease, peripheral polyneuropathy, 336
- rehabilitation
 - aims, 582–3
 - disability, reduction, 592
 - impairment, interventions to reduce, 591–2
 - neuropsychology of recovery, 567–80
 - objectives, 583
 - outcomes, 581–96
 - effectiveness, 587–90
 - evidence, 588–9
 - measurements, 586
 - specific components
 - assessment, 590
 - goal planning, 591
- renal transplantation, Fabry’s disease, 336
- reticular formation lesion, coma, 463
- reversible ischaemic neurological deficit (RIND), 62
- rhizotomy
 - facet, 483–5
 - partial sensory in trigeminal neuralgia, 522–4
 - spasmodic torticollis, 547
- rubella virus infections, 395
- sacral chordomas, 212–13, 234
- SAH *see* subarachnoid haemorrhage
- Schwann cells, and demyelination disorders, 329, 343
- schwannomas, treatment, 228–30
- SDH *see* subdural haematoma
- seizures
 - bacterial meningitis, 361
 - brain tumours, 221
 - chronic partial, herpes simplex encephalitis, 394
 - classification, 408, 410–11
 - clinical features, and rate of recurrence, 5
 - discontinuation of anticonvulsants, 417
 - efficacy of prophylaxis, 173
 - epileptic, herpes simplex encephalitis in children, 394
 - prognosis, first unprovoked, 409–15
 - severity scales, 25–6
 - see also* epilepsy
- sensorimotor polyneuropathy
 - HIV-associated, 343–4
 - vasculitic neuropathy, 343
- sensory nerve action potentials (SNAPs),
 - depression in neuropathy, 346
- sensory neuropathy, inflammatory (ganglionitis), 343
- Sickness Impact Profile, 10
- Sjögren syndrome
 - trigeminal neuropathy, 343
 - vasculitic neuropathy, 343
- small-artery disease, cerebral infarction, 67
- somatosensory evoked potentials (SSEP), 241
 - cortical (N20) component, outcome in HSE, 391–2
- spasmodic torticollis, rhizotomy, 547
- spasticity, impairment, interventions, 591–2
- speech therapy
 - aphasia, 44
 - and language function, 592
 - multiplicity of outcomes, 7–8
- spinal AVMs
 - classification, 135
 - functional grading scale, 135
 - see also* arteriovenous malformations, spinal
- spinal cord
 - compression, 267
 - MRI, 50, 185
 - intraparenchymal haemorrhage, 62
 - lesions
 - descriptions and scales, 181–5
 - progressive, 186–7
- spinal cord injuries, 181–92
 - C3–C7 lesions, rehabilitation, 189–83
 - descriptions, scales and outcomes, 181–5
 - Frankel Classification, 181–3
 - functional independence measure (FIM), 183
 - IMSOP/ASIA standards, muscles/sensory points, 184
 - life expectancy, 186
 - MRI, prognostic value, 50, 185
 - neurological outcome, 187
 - nursing and therapy, 189–90
 - pharmacological interventions, 188–9
 - surgical interventions, 187–8
 - tetraplegia, survival outcome, 185–6

- spinal cord stimulation, 533–46
 - complications and technical problems, 541, 542
 - dorsal column stimulation failure, 540–1
 - mechanisms, 533–5
 - patient selection, 535
 - permanent stimulator implantation, 536–7
 - results, 537–40
 - trial, 536
- spinal degenerative disease, 267–88
 - cervical laminectomy, 269–70
 - Functional-Economic Outcome Rating Scale, 276
 - herniated lumbar disc
 - chemonucleolysis, 277
 - percutaneous discectomy, 277
- spinal mechanical disorders, 267–88
- spinal meningeal fibrosis, 479
- spinal stabilization
 - Harrington rods, 235
 - intertransverse-process fusion, 281–2
 - pedicle screw fixation, 281
 - posterolateral fusion, 281
- spinal tumours, 227–35
 - aneurysmal bone cyst, 234
 - extradural, 233–5
 - treatment, 234–5
 - intradural
 - extramedullary, 227–30
 - see also* meningioma; schwannoma
 - intramedullary
 - diagnostic imaging, 230–1
 - incidence and clinical signs, 230
 - treatment, 232–3
 - laminectomy, 228–30, 235
- spirochaetal diseases, 365
 - meningoradiculitis, 344
- spongiform encephalopathies, 403
- stereotactic surgery, movement disorders, 547–66
- Streptococcus pneumoniae*
 - bacterial meningitis, 357–62
 - neonatal meningitis, 363
- stroke, 19–20, 61–92
 - classifications, 63
 - computed tomography, 36
 - cost-benefit analysis, choices for practitioners, 36
 - definitions, 61–2
 - depression, 22
 - epidemiology, 63–6
 - epilepsies, 18–29
 - incidence and secular trends, 63
 - increased risk, 64
 - mitochondrial dysfunction, 68
 - neuropsychological impairment, course of
 - recovery, 572–4
 - neuropsychological processes
 - compensation, 569
 - inhibition, 568–9
 - motivation and emotion, 572
- outcomes
 - assessment of outcome, ADLs, 573
 - cognitive impairment, 23
 - commonly used scales, 25
 - disability consequence, 76–7
 - functional ability, 21–2
 - functional adaptation, 569–72
 - functional and social consequences, 76
 - handicap, defined, 78–9
 - homecoming, predictors affecting, 78
 - life satisfaction, definition and scales, 23–4
 - multiplicity of outcomes, 7–9
 - predictors of disability, 77
 - predictors of recovery, 76–7
 - psychiatric morbidity, 22–3
 - quality of life, 78–9
 - RAND Medical Outcomes Survey, 23
 - recovery spans, 21
 - recurrence risk, statistics, 79
 - return to work, 78
 - services, 19
 - studies, outcome measures, 21
 - young/elderly patient, comparison, 68
- prevention, 66, 81–2
 - meta-analyses, 81–2
 - statistics, 5
- psychiatric morbidity, measurement scales, 22–3
- rehabilitation
 - aims and objectives, 582–3
 - assessment and planning, 590–1
 - measuring effectiveness, 584–5
 - meta-analytic review, 574–7
 - neuropsychology of recovery, 567–80
 - outcome determinants, 585–7
 - outcome effectiveness, 587–90
 - outcome evidence, 588–9
 - process, four stages, 583
 - reduction of fatality rate, 590
- right hemispheric, unilateral left neglect, 568
- risk factors, 63–6
 - age, 63–4
 - cholesterol level, 64
 - cigarette smoking, 65
 - diet, 65
 - hormone replacement therapy, 65
 - hypertension, 64–5
 - intermittent claudication, 65–6
 - oral contraceptives, 65
- risk reduction, anti-platelet drug treatment, 82
- treatment
 - hospital admission, 79–80
 - medical treatment, 80–3
 - and prognosis, 72
 - surgical treatment, 82–3

- TyPE tool, 19–20
 - acute stroke, 19–20
- see also* cerebral vascular accident
- subacute sclerosing panencephalitis (SSPE), 395
- subarachnoid haemorrhage, 93–122
- aetiology, 101
- age and surgical outcome, 105
- AVM, 123
- complications, 109–12
 - hydrocephalus, 110
 - rerupture, 109–10
- computed tomography, 98
- Fisher’s CT scan classification, 100
- grading systems, 98, 99
- haematoma, CT, 48
- historical information, 93–4
- mass effect, 97–8, 105
- medical vs surgical treatment, 99
- neuroradiological treatment, 106–9
- ruptured aneurysm, 99–100
- surgical options and outcome, 101–9
 - admission grade/surgical results, 102
 - Botterell grades, 104
 - early/late, advantages/disadvantages, 105
 - optimum procedures, 102–3
 - vasospasm period, 105–6
- surgical outcome, factors affecting, 112
- surgical treatment alternatives, 106–9
- supratentorial lesion, coma, 463
- syringomyelia, 478–80
 - defined, 478
 - hindbrain-related, 478–9
 - spinal meningeal fibrosis, 479
- systemic inflammatory response syndrome (SIRS), 345–6
- systemic sclerosis, trigeminal neuropathy, 343
- Systemmetrics, 6
- T-cell leukaemia, human T-cell lymphotropic viruses, 396–7
- tabes dorsalis, syphilis, 365
- Tangier disease, peripheral polyneuropathy, 336
- temporal artery, superior, STA-MCA bypass, 108–9
- temporal lobe sclerosis, MRI, 49
- temporal lobectomy
 - for epilepsy, 421–9
 - Temporal Lobe Club, 25
- tenotomy, 591
- tetraplegia, defined, 181
- thalamic infarcts, 69
- thalamotomy, 492–3
 - bilateral
 - complications, 555–6
 - results, 553–4
 - cerebellar complications, 555
 - dystonia (DMD), 558–61
 - essential and cerebellar tremor, 557–8
 - indications, 549
 - Parkinson’s disease
 - complications, 553
 - effect on progress, 556–7
 - mechanism, 550
 - outcomes, 551–2
 - technique, 549–50
 - unilateral, 552–3
- thalidomide, toxic neuropathy, 346
- therapy and therapists, 592
- thiamine deficiency, 339
- thromboembolism, cerebral arteries, CT, 48
- thrombolysis
 - aetiology of ICH, 73
 - anticoagulation, 73
 - intra-arterial, 54
- tick-associated disease, Lyme disease, 344, 366
- ticlopidine, alternative to aspirin, 72, 81
- tissue plasminogen activator, intraventricular haemorrhage, 97
- tomography, X-ray, 44
- tonsillar prolapse, 478
- toxic neuropathy, 346
- tPA *see* tissue plasminogen activator
- tractotomy, mesencephalic, 490–1
- transient hemispherical attack (THA), 70
- transient ischaemic attacks (TIA), 61–2, 70–3
 - aetiology, 71
 - clinical manifestations, 70–1
 - diagnosis and differential diagnosis, 71
 - prognosis and treatment, 72
 - prolonged RIND, 62
- transient monocular blindness (TMB), 70–2
- transthyretin, in familial amyloid polyneuropathy, 335
- transverse-sigmoid sinus junction, 128
- traumatic injury
 - peripheral nerves, 347–8
 - Trauma Coma Data Bank (TCDB), 159, 161, 167
 - see also* head injury
- tremor
 - cerebellar, 551
 - thalamotomy, 548
- Treponema pallidum*, syphilis, 365
- trigeminal neuralgia, 343, 507–32
 - chronic neurostimulation of gasserian ganglion, 528
 - medical therapy, 508–9
 - nucleus caudalis DREZ lesion, 526–8
 - retrograde adriamycin sensory ganglionectomy, 528
 - surgical treatment, 509–28
 - microvascular decompression, 516–22
 - partial sensory rhizotomy, 522–4

- percutaneous radiofrequency trigeminal gangliolysis, 512–14
- trigeminal neuralgia, surgical treatment (*cont.*)
 - percutaneous retrogasserian glycerol rhizolysis, 510–12
 - percutaneous trigeminal ganglion (micro)compression, 514–16
 - trigeminal tractotomy, 524–6
- trigeminal neuroma, 205
 - resection complications, 204
- tropical spastic paresis, 397
- tuberculous meningitis, 364–5
- tumour necrosis factor, MS, 252
- tumours, metabolism
 - MRI, 50
 - PET, 53
- unilateral hemisphere lesion, coma, 463
- uraemic neuropathy, 339
- urinary incontinence, stroke, as predictor of disability, 77
- urokinase, intraventricular haemorrhage, 97
- varicella–zoster virus infections, 397–8
- vascular lesions
 - MRI, 49
 - see also* endovascular therapy
- vasculitic neuropathy, 343
- vasospasm
 - angiographic
 - balloon occlusion contraindications, 107
 - diagnostic evaluation, 53
 - delayed cerebral arterial, 110–12
 - endovascular therapy, 56
 - vegetative state, differentiation from coma, 462
- vein of Galen AVM, 130–1
 - natural history, modes of treatment, 131
- venous angiomas, 123
- venous sinus thrombosis, MRI, 49
- ventilation, weaning from, SIRS and critical illness polyneuropathies, 345–6
- ventriculography, history, 47
- vertebrectomy, 272–3
- vidarabine, herpes simplex encephalitis, 388–90, 394
- vincristine, toxic neuropathy, 346
- viral infections, 385–405
- viral myositis, 310
- visual evoked potential (VEP), 241
- vitamins B and E, deficiency-associated polyneuropathies, 339
- Von Recklinghausen's disease, 228–9
- warfarin, stroke prevention, 81, 82
- Washington Psychosocial Inventory, epilepsies, 28
- Wechsler Memory Scale, 27
- World Federation of Neurological Surgeons (WFNS), 98–9
 - grading of SAH, 103
- World Health Organization (WHO), health status indicators, 16
- X-ray tomography, 44
- Xp21 deletion myopathies, 312
- yellow fever, 395–6